Virginia life sciences entrepreneur Josep Bassaganya-Riera’s latest company NImmune Biopharma launched with an eye on a potential New Drug Application for its Phase III-ready experimental therapeutic for ulcerative colitis.
NImmune Biopharma’s lead asset is the clinical candidate omilancor, which it secured in February from Landos Biopharma, a company Bassaganya-Riera founded in 2017. Along with omilancor, NImmune gained the rights to Landos’ LANCL portfolio of immunoregulatory therapeutic assets, which also includes assets previously known as LABP-104 and LABP-111. These assets are designed to activate the Lanthionine Synthetase C-Like 2 (LANCL2) pathway, which enhances immunoregulatory processes that provide protection from autoimmune disease. Each of these assets were originally developed by Bassaganya-Riera, who served as chief executive officer of Landos until his departure from the company in November 2021.
